Juncture Wealth Strategies LLC Acquires New Position in Insulet Co. (NASDAQ:PODD)

Juncture Wealth Strategies LLC bought a new position in Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 878 shares of the medical instruments supplier’s stock, valued at approximately $229,000.

Several other large investors also recently added to or reduced their stakes in PODD. QRG Capital Management Inc. acquired a new stake in shares of Insulet in the third quarter worth $297,000. Fisher Asset Management LLC increased its holdings in Insulet by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after buying an additional 3,113 shares during the period. Orion Portfolio Solutions LLC increased its holdings in Insulet by 86.2% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock valued at $1,822,000 after buying an additional 3,623 shares during the period. Nomura Asset Management Co. Ltd. increased its position in shares of Insulet by 5.7% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock worth $35,708,000 after purchasing an additional 8,301 shares in the last quarter. Finally, Stifel Financial Corp increased its position in shares of Insulet by 2.8% during the 3rd quarter. Stifel Financial Corp now owns 10,527 shares of the medical instruments supplier’s stock worth $2,450,000 after purchasing an additional 290 shares in the last quarter.

Insider Activity

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by company insiders.

Insulet Price Performance

NASDAQ PODD opened at $280.35 on Friday. The company has a market capitalization of $19.66 billion, a PE ratio of 48.01, a price-to-earnings-growth ratio of 3.50 and a beta of 1.22. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $282.86. The firm’s 50 day moving average is $267.25 and its 200-day moving average is $235.53. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. The business had revenue of $543.90 million for the quarter, compared to the consensus estimate of $518.50 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. During the same period in the previous year, the company earned $0.71 earnings per share. Equities research analysts anticipate that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on PODD shares. Canaccord Genuity Group raised their price objective on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th. BTIG Research raised their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Citigroup raised their price objective on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Barclays lifted their price target on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Finally, Sanford C. Bernstein initiated coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $272.81.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.